The Addition of Darolutamide to ADT Reduces Risk of Metastasis in Nonmetastatic CRPC

The Addition of Darolutamide to ADT Reduces Risk of Metastases in CRPCПодробнее

Assessing the Role of Darolutamide in CRPCПодробнее

Understanding Nonmetastatic CRPC: An OverviewПодробнее

Darolutamide’s Role in Treating Nonmetastatic CRPCПодробнее

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPCПодробнее

Dr. Fizazi on Darolutamide-Based Therapy in Nonmetastatic CRPCПодробнее

ARAMIS: darolutamide in patients with nmCRPCПодробнее

Darolutamide for nmCRPC: results of the ARAMIS trialПодробнее

FDA Approves Bayer's Nubeqa (Darolutamide) for Non-Metastatic Castration-Resistant Prostate CancerПодробнее

Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPCПодробнее

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPCПодробнее

ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancerПодробнее

The ARAMIS Trial in M0 CRPCПодробнее

Dr. Tagawa Discusses Darolutamide in CRPCПодробнее

Interaction of darolutamide with substrates of CYPs and P-gpПодробнее

Nonmetastatic CRPC: meeting an unmet needПодробнее

AUA2019 027IC: AUA CRPC Guidelines and Therapeutic Advances in Metastatic Prostate CancerПодробнее

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate CancerПодробнее

Achieving MFS and Improved Quality of Life in nmCRPC With DarolutamideПодробнее

Dr. Lee on the Role of Darolutamide in M0CRPCПодробнее
